Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Lleo

Showing results (181-190 of 202) with videos related to

Pageof 21
Sort By:
European Journal of Gastroenterology & Hepatology|December 5, 2022
Geographical region and clinical outcomes of patients with primary biliary cholangitis from Western EuropeCarla F Murillo Perez, Alessio Gerussi, Palak J Trivedi, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 8, 2019
Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary CholangitisAngela C Cheung, Willem J Lammers, Carla F Murillo Perez, et al.
The American Journal of Gastroenterology|July 4, 2020
Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline PhosphataseCarla F Murillo Perez, Maren H Harms, Keith D Lindor, et al.
Gut|September 27, 2023
Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapyColm J O'Rourke, Massimiliano Salati, Colin Rae, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 9, 2023
Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one-year non-responders and predicts survivalC Fiorella Murillo Perez, Stephanie Ioannou, Iman Hassanally, et al.
JHEP Reports : Innovation in Hepatology|November 28, 2022
Histological and serological features of acute liver injury after SARS-CoV-2 vaccinationGreta Codoni, Theresa Kirchner, Bastian Engel, et al.
Hepatology (Baltimore, Md.)|June 13, 2025
Refinement of histologic subtypes and identification of biomarkers linked to unfavorable prognosis in cholangiocarcinoma: The ENSCCA registries' framework for digital twin advancementGuido Carpino, Diletta Overi, Rocio Ir Macias, et al.
Nature Reviews. Gastroenterology & Hepatology|December 10, 2025
Cholangiocarcinoma 2026: status quo, unmet needs and prioritiesJesus M Banales, Pedro M Rodrigues, Silvia Affò, et al.
Human Molecular Genetics|September 1, 2012
Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variantsBrian D Juran, Gideon M Hirschfield, Pietro Invernizzi, et al.
European Journal of Gastroenterology & Hepatology|January 28, 2026
Clinical course and prognostic risk factors of SARS-CoV-2 vaccine-related hepatitis: differentiating severe acute respiratory syndrome coronavirus 2 vaccine-associated liver injury from autoimmune hepatitisDonald Malino, Greta Codoni, Theresa Kirchner, et al.
Pageof 21

Showing results (181-190 of 202) with videos related to

Sort By:
Pageof 21
European Journal of Gastroenterology & Hepatology|December 5, 2022
Geographical region and clinical outcomes of patients with primary biliary cholangitis from Western EuropeCarla F Murillo Perez, Alessio Gerussi, Palak J Trivedi, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 8, 2019
Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary CholangitisAngela C Cheung, Willem J Lammers, Carla F Murillo Perez, et al.
The American Journal of Gastroenterology|July 4, 2020
Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline PhosphataseCarla F Murillo Perez, Maren H Harms, Keith D Lindor, et al.
Gut|September 27, 2023
Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapyColm J O'Rourke, Massimiliano Salati, Colin Rae, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 9, 2023
Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one-year non-responders and predicts survivalC Fiorella Murillo Perez, Stephanie Ioannou, Iman Hassanally, et al.
JHEP Reports : Innovation in Hepatology|November 28, 2022
Histological and serological features of acute liver injury after SARS-CoV-2 vaccinationGreta Codoni, Theresa Kirchner, Bastian Engel, et al.
Hepatology (Baltimore, Md.)|June 13, 2025
Refinement of histologic subtypes and identification of biomarkers linked to unfavorable prognosis in cholangiocarcinoma: The ENSCCA registries' framework for digital twin advancementGuido Carpino, Diletta Overi, Rocio Ir Macias, et al.
Nature Reviews. Gastroenterology & Hepatology|December 10, 2025
Cholangiocarcinoma 2026: status quo, unmet needs and prioritiesJesus M Banales, Pedro M Rodrigues, Silvia Affò, et al.
Human Molecular Genetics|September 1, 2012
Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variantsBrian D Juran, Gideon M Hirschfield, Pietro Invernizzi, et al.
European Journal of Gastroenterology & Hepatology|January 28, 2026
Clinical course and prognostic risk factors of SARS-CoV-2 vaccine-related hepatitis: differentiating severe acute respiratory syndrome coronavirus 2 vaccine-associated liver injury from autoimmune hepatitisDonald Malino, Greta Codoni, Theresa Kirchner, et al.
Pageof 21